12.42
-0.3(-2.36%)
Currency In USD
| Previous Close | 12.72 |
| Open | 12.74 |
| Day High | 12.91 |
| Day Low | 12.33 |
| 52-Week High | 27.5 |
| 52-Week Low | 4.81 |
| Volume | 177,470 |
| Average Volume | 285,500 |
| Market Cap | 415.13M |
| PE | -5.65 |
| EPS | -2.2 |
| Moving Average 50 Days | 9.37 |
| Moving Average 200 Days | 15.05 |
| Change | -0.3 |
If you invested $1000 in MBX Biosciences, Inc. Common Stock (MBX) since IPO date, it would be worth $525.16 as of June 01, 2025 at a share price of $12.42. Whereas If you bought $1000 worth of MBX Biosciences, Inc. Common Stock (MBX) shares 0 years ago, it would be worth $525.16 as of June 01, 2025 at a share price of $12.42.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MBX Biosciences to Participate in June Investor Conferences
GlobeNewswire Inc.
May 20, 2025 12:00 PM GMT
CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metaboli
MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire Inc.
May 12, 2025 12:00 PM GMT
Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable secu
MBX Biosciences to Participate in Citizens and RBC May Investor Conferences
GlobeNewswire Inc.
Apr 22, 2025 12:00 PM GMT
CARMEL, Ind., April 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabo